TABLE 3.
Baseline clinical and lesion characteristics and medications in the index AMI
| Total (n = 74) | HFpEF (n = 30) | HFmrEF (n = 20) | HFrEF (n = 24) | HFmrEF vs. HFpEF | HFrEF vs. HFpEF | HFmrEF vs. HFrEF | ||
|---|---|---|---|---|---|---|---|---|
| Age (years) | 74.7 ± 12.1 | 75.6 ± 10.3 | 74.8 ± 11.9 | 73.4 ± 14.7 | 0.953 | |||
| Sex: female, n (%) | 24 (32.4) | 8 (26.7) | 8 (40.0) | 8 (33.3) | 0.611 | |||
| Medical history | ||||||||
| Smoking, n (%) | 51 (68.9) | 23 (76.7) | 13 (65.0) | 15 (62.5) | 0.479 | |||
| Diabetes mellitus, n (%) | 30 (40.5) | 11 (36.7) | 8 (40.0) | 11 (45.8) | 0.792 | |||
| Hypertension, n (%) | 49 (66.2) | 23 (76.7) | 14 (70.0) | 12 (50.0) | 0.113 | |||
| Dialysis, n (%) | 5 (6.8) | 1 (3.3) | 3 (15.0) | 1 (4.2) | 0.271 | |||
| Killip class | ||||||||
| IV, n (%) | 12 (16.2) | 5 (16.7) | 3 (15.0) | 4 (16.7) | 0.985 | |||
| STEMI, n (%) | 60 (81.1) | 22 (73.3) | 16 (80.0) | 22 (91.7) | 0.201 | |||
| Laboratory data in the index AMI admission | ||||||||
| Hb (g/dL) | 12.9 ± 2.4 | 12.6 ± 2.8 | 12.9 ± 2.1 | 13.4 ± 2.0 | 0.432 | |||
| eGFR (mL/min/1.73 m2) | 55.7 ± 32.9 | 52.2 ± 27.1 | 54.6 ± 44.9 | 61.1 ± 28.0 | 0.489 | |||
| LDL‐C (mg/dL) | 102.8 ± 39.2 | 98.8 ± 39.4 | 105.2 ± 47.0 | 106.0 ± 33.0 | 0.516 | |||
| HDL‐C (mg/dL) | 46.0 ± 13.0 | 46.2 ± 14.0 | 45.5 ± 12.7 | 46.0 ± 12.6 | 0.960 | |||
| BNP (pg/mL) | 395.6 (141.5–841.1) | 501.1 (196.0–1095.7) | 301.0 (233.3–736.8) | 289.2 (100.5–853.1) | 0.459 | |||
| Max CK (IU/L) | 2604 (1215–4675) | 2111 (927–4193) | 2964 (1333–5957) | 4001 (1470–4921) | 0.384 | |||
| Max CK (IU/L) ≥ 2000 | 43 (58.1) | 15 (50.0) | 13 (65.0) | 15 (62.5) | 0.499 | |||
| EF (%) | 52.0 ± 11.9 | 58.3 ± 9.7 | 53.3 ± 10.2 | 43.3 ± 10.5 | <0.001 | 0.081 | <0.001 | 0.004 |
| Culprit vessel | ||||||||
| RCA, n (%) | 19 (25.7) | 9 (30.0) | 5 (25.0) | 5 (20.8) | 0.742 | |||
| LAD, n (%) | 43 (58.1) | 18 (60.0) | 8 (40.0) | 17 (70.8) | 0.113 | |||
| LCX, n (%) | 7 (9.5) | 2 (6.7) | 4 (20.0) | 1 (4.2) | 0.192 | |||
| LMT, n (%) | 2 (2.7) | 0 | 2 (10.0) | 0 | 0.068 | |||
| Final TIMI flow grade | ||||||||
| 3, n (%) | 69 (93.2) | 29 (96.7) | 18 (90.0) | 22 (91.7) | 0.589 | |||
| Medications at discharge in the index AMI admission | ||||||||
| Aspirin, n (%) | 70 (94.6) | 28 (93.3) | 18 (90.0) | 24 (100.0) | 0.181 | |||
| ACEIs or ARBs, n (%) | 69 (93.2) | 28 (93.3) | 19 (95.0) | 22 (91.7) | 0.907 | |||
| ACEIs, n (%) | 62 (83.8) | 23 (76.7) | 18 (90.0) | 21 (87.5) | 0.384 | |||
| ARBs, n (%) | 13 (17.6) | 8 (26.7) | 3 (15.0) | 2 (8.3) | 0.191 | |||
| Beta‐blockers, n (%) | 51 (68.9) | 20 (66.7) | 14 (70.0) | 17 (70.8) | 0.941 | |||
| Loop diuretics, n (%) | 51 (68.9) | 21 (70.0) | 12 (60.0) | 18 (75.0) | 0.560 | |||
| MR blockers | 18 (24.3) | 8 (26.7) | 3 (15.0) | 7 (29.2) | 0.489 | |||
| Statins, n (%) | 37 (50.0) | 13 (43.3) | 13 (65.0) | 11 (45.8) | 0.282 | |||
AMI, acute myocardial infarction; HFmrEF, heart failure with mid‐range left ventricular ejection fraction; HFpEF, heart failure with preserved left ventricular ejection fraction; HFrEF, heart failure with reduced left ventricular ejection fraction. Other abbreviations as in Table 1 .